Pacira BioSciences (PCRX) Price to Sales (2011 - 2026)

Pacira BioSciences has reported Price to Sales for 16 years, with the latest figure at 5.25 in Q2 2026.

• On a quarterly basis, Price to Sales fell 11.38% year-over-year to 5.25 in Q2 2026; TTM through Jun 2026 was 1.35, a 10.94% decrease from a year earlier, with the FY2025 full-year figure at 1.46, up 17.87% from the prior year.
• Price to Sales was 5.25 for Q2 2026 at Pacira BioSciences, up from 5.01 in the prior quarter.
• The five-year high for Price to Sales was 21.77 in Q1 2022, with the low at 4.12 in Q3 2024.
• Average Price to Sales over 5 years is 8.96, with a median of 7.77 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Price to Sales slumped 52.58% in 2024, then surged 49.7% in 2025.
• Over 5 years, Price to Sales stood at 10.31 in 2022, then decreased by 16.09% to 8.65 in 2023, then tumbled by 46.23% to 4.65 in 2024, then grew by 16.18% to 5.41 in 2025, then fell by 2.85% to 5.25 in 2026.
• The last three Price to Sales figures came in at 5.25 (Q2 2026), 5.01 (Q1 2026), and 5.41 (Q4 2025), per Business Quant data.